Eosinophilic Esophagitis Market Forecast to Reach Over USD 3,543 Million by 2036

The Eosinophilic Esophagitis (EoE) market size was valued at approximately ~USD 901 million in 2025 and is anticipated to reach approximately ~USD 3,543 million, growing at a significant CAGR of 12.9% during the study period (2022–2036). DelveInsight's comprehensive market research provides critical insights into such market trends, enabling stakeholders to understand growth drivers, emerging opportunities, and potential challenges within the EoE landscape.

In 2025, the U.S. market size was estimated at approximately USD 650 million, projected to reach approximately USD 2,800 million by 2036, growing at a CAGR of 14% during 2026–2036. The United States contributed the largest diagnosed prevalent cases of EoE, accounting for approximately ~72% of the 7MM in 2025. Currently, three therapies are approved for EoE: budesonide oral dispersible tablet (JORVEZA) in Europe (2018, adults), dupilumab (DUPIXENT), the first and only biologic therapy (US, 2022; approved for patients age 1 and older; also approved in Europe), and budesonide oral suspension (EOHILIA) (US, 2024, patients 11 years and older). Dupilumab covers a broader patient population and holds a strong market position over these more restricted therapies.

By analyzing historical data, current market dynamics, and future projections, DelveInsight equips pharmaceutical companies, investors, and healthcare professionals with actionable intelligence to make informed strategic decisions, identify investment opportunities, optimize product positioning, and plan research and development initiatives effectively.

In the 7MM, the US accounted for the highest diagnosed prevalent cases of eosinophilic esophagitis in 2025, with around 512,000 cases. EoE predominantly affected males, with approximately 332,000 males diagnosed compared to 179,000 females in the US in 2025. In the EU4 and the UK, individuals over the age of 18 were the most affected by EoE, with approximately 395,000 cases reported in 2025.

DelveInsight's report, "Eosinophilic Esophagitis Market Insight, Epidemiology, and Market Forecast – 2036," provides a comprehensive analysis of the EoE landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the prevalence, incidence, and patient demographics across key regions.

Additionally, it examines EoE market dynamics, offering a thorough assessment of current and emerging market trends, treatment patterns, and therapeutic developments. The analysis spans major markets, including the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan, equipping decision-makers with actionable intelligence for strategic planning, investment, and research initiatives.

To know in detail about the Eosinophilic Esophagitis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here — Eosinophilic Esophagitis Market Insights

Key Facts of the Eosinophilic Esophagitis Market Report

• Key Eosinophilic Esophagitis Companies: AstraZeneca and Amgen, Ellodi Pharmaceuticals, Revolo Biotherapeutics, Phathom Pharmaceuticals, Uniquity Bio, EsoCap AG, DBV Technologies, Eupraxia Pharmaceuticals, and others
• Key Eosinophilic Esophagitis Therapies: DUPIXENT (dupilumab), EOHILIA (budesonide oral suspension), JORVEZA (budesonide ODT), TEZSPIRE (tezepelumab), APT-1011, IRL201104, VOQUEZNA (vonoprazan), Solrikitug, ESO-101, EP-104GI, and others
• The EoE market is expected to grow due to increasing disease awareness and diagnosis, rising prevalence of allergic disorders, and advancements in targeted biologic therapies during the forecast period. Furthermore, the launch of multiple late-stage pipeline candidates poised to challenge DUPIXENT will significantly influence the EoE market dynamics.

Eosinophilic Esophagitis Overview

Eosinophilic Esophagitis (EoE) is an emerging chronic inflammatory disease of the esophagus characterized by upper gastrointestinal symptoms, including dysphagia and esophageal food impaction. The histopathological manifestations involve intraepithelial infiltration of eosinophils (≥15 Eos/HPF) and remodeling of the esophageal epithelium, including basal zone hyperplasia and dilated intercellular spaces, which can lead to strictures and narrow-caliber esophagus. Clinical and experimental evidence suggests EoE is driven by an underlying CD4+ T helper type 2 (Th2) allergic inflammatory response to dietary food allergens in the esophageal mucosa.

The gold standard for diagnosing and monitoring EoE remains esophageal biopsy demonstrating eosinophilic infiltration limited to the esophagus. However, diagnosis is challenging due to non-specific, overlapping symptoms and the absence of validated noninvasive biomarkers, often leading to delayed identification. First-line treatment typically involves proton pump inhibitors (PPIs); however, many patients do not achieve adequate response, and management often progresses to swallowed topical corticosteroids or biologics, alongside non-pharmacologic options such as food elimination diets and esophageal dilation.

Request the sample page for the Eosinophilic Esophagitis Market Report

Key Trends in Eosinophilic Esophagitis Therapeutics Market

• Increasing Disease Awareness and Diagnosis: Improved recognition of EoE among clinicians and advancements in endoscopic and biopsy-based diagnostics are leading to higher diagnosis rates.
• Rising Prevalence of Allergic Disorders: The growing incidence of food allergies, asthma, and other atopic conditions is contributing to an expanding patient pool for EoE.
• Advancements in Targeted Therapies: The emergence of biologics and novel anti-inflammatory agents, including monoclonal antibodies targeting IL-4, IL-5, and IL-13 pathways, is transforming treatment approaches.
• Growing Focus on Pediatric and Adult Treatment Options: Increased research across both pediatric and adult populations is driving demand for safe, long-term therapies.
• Regulatory Support and Drug Approvals: Favorable regulatory pathways, including orphan drug designations and recent approvals of EoE-specific therapies, are accelerating market growth.
• Diversifying Administration Routes: Novel approaches such as EP-104GI's once-yearly submucosal injection and IRL201104's sublingual tablet are addressing unmet needs not fully met by approved therapies.

Eosinophilic Esophagitis Epidemiology

The EoE epidemiology chapter provides historical as well as forecasted epidemiology segmented by total diagnosed prevalent cases, gender-specific cases, age-specific cases, and treated cases in the 7MM, covering the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan from 2022 to 2036.

Eosinophilic Esophagitis Epidemiology Segmentation

The EoE market report proffers epidemiological analysis for the study period 2022–2036 in the 7MM, segmented into:

• Total Diagnosed Prevalent Cases of Eosinophilic Esophagitis
• Gender-specific Cases of Eosinophilic Esophagitis
• Age-specific Cases of Eosinophilic Esophagitis
• Treated Cases of Eosinophilic Esophagitis

Download the report to understand which factors are driving Eosinophilic Esophagitis epidemiology trends @ Eosinophilic Esophagitis Epidemiology Forecast

Recent Developments in the Eosinophilic Esophagitis Treatment Landscape

• In June 2026: Preclinical contract research organization HKeyBio launched HKEY-ExE 1.0, an evaluation framework for EoE and eosinophilic gastroenteritis, integrating automated disease modeling, multi-dimensional efficacy endpoint assessment, and biomarker analysis for type 2 inflammation.
• In June 2026: Phathom Pharmaceuticals completed patient enrollment ahead of schedule for its Phase 2 pHalcon-EoE-201 trial evaluating VOQUEZNA (vonoprazan) as an investigational, non-steroidal oral treatment for adults with EoE.
• In May 2026: Sanofi and Regeneron announced positive results from the REMODEL Phase 4 trial evaluating Dupixent in adults with EoE at DDW 2026, demonstrating significantly improved esophageal distensibility and reversal of disease-related structural damage over 24 weeks.
• In May 2026: Sanofi Medical presented clinical data from the Phase 4 REMODEL study at DDW 2026, showing Dupixent achieved a 59% histologic remission rate in EoE patients compared to just 4% for placebo.
• In May 2026: Takeda Pharmaceuticals launched the "Finding the Words" campaign to raise awareness of the diagnostic journey of EoE, featuring real-world patient testimonials.
• In January 2026: Phathom Pharmaceuticals anticipates topline data in 2027 from its Phase II clinical trial (pHalcon-EoE-201) in patients with EoE.
• In August 2025: Revolo Biotherapeutics announced its decision to accelerate the advancement of a sublingual tablet (IRL201104) to enter the clinic in 2026.
• In May 2025: Eupraxia Pharmaceuticals announced positive treatment outcomes from its ongoing RESOLVE Phase Ib/IIa trial, disclosing 9-month data showing all three patients dosed at 48mg of EP-104GI experienced sustained or improved treatment outcomes.

Eosinophilic Esophagitis Drugs Uptake and Pipeline Development Activities

The EoE market shows a clear uptake split between established therapies and newer targeted agents. PPIs, swallowed topical corticosteroids, and dietary therapy remain dominant in first-line use due to guideline support and long-standing clinical experience, while biologics such as DUPIXENT have seen rapid uptake in refractory patients driven by strong efficacy and disease-targeted mechanisms. Emerging pipeline agents are expected to experience more gradual adoption as clinical evidence matures and guideline integration evolves.

Most emerging EoE therapies have received orphan drug designation from the US FDA, including Velsipity, TEZSPIRE, APT-1011, ESO-101, and IRL201104. Among these, only APT-1011 has a Fast Track designation and is expected to be the first to reach the market, providing a competitive edge.

Eosinophilic Esophagitis Approved and Emerging Therapies

• Dupilumab (DUPIXENT): Sanofi/Regeneron Pharmaceuticals; approved in the US in 2022 and EU in 2023.
• Budesonide ODT (JORVEZA): Dr. Falk Pharma GmbH; approved in the EU in 2018.
• Budesonide oral suspension (EOHILIA): Takeda; approved in the US in 2024.
• Tezepelumab (TEZSPIRE): AstraZeneca and Amgen; Phase III, with CROSSING trial data expected in H2 2026.
• APT-1011 (fluticasone propionate): Ellodi Pharmaceuticals; Phase III (FLUTE 3), with FTD and ODD designations granted.
• IRL201104: Revolo Biotherapeutics; Phase II, sublingual formulation.
• Vonoprazan (VOQUEZNA): Phathom Pharmaceuticals; Phase II, PCAB therapy.
• Solrikitug (NSI-8226): Uniquity Bio; Phase II, TSLP inhibitor.
• ESO-101: EsoCap AG; Phase II, glucocorticoid receptor agonist.
• EP-104GI: Eupraxia Pharmaceuticals; Phase I/II, once-yearly submucosal injection.

In 2025, DUPIXENT led the US EoE treatment market and is projected to retain its position as the dominant market leader through 2036. PPI treatment for EoE generated approximately USD 346 million in revenue across the 7MM countries in 2025.

To know more about Eosinophilic Esophagitis companies working in the treatment market, visit @ Eosinophilic Esophagitis Clinical Trials and Therapeutic Assessment

Eosinophilic Esophagitis Market Drivers

• Increasing disease awareness and diagnosis through improved recognition among clinicians and advancements in endoscopic and biopsy-based diagnostics
• Rising prevalence of allergic disorders, including food allergies, asthma, and other atopic conditions, expanding the patient pool
• Advancements in targeted therapies, including biologics and novel anti-inflammatory agents targeting IL-4, IL-5, and IL-13 pathways
• Growing focus on pediatric and adult treatment options, driving demand for safe, long-term therapies
• Regulatory support and drug approvals, including orphan drug designations and recent EoE-specific therapy approvals
• Diversifying administration routes, including sublingual and once-yearly submucosal injection formats, addressing gaps left by approved therapies

Eosinophilic Esophagitis Market Barriers

• Lack of reliable, non-invasive diagnostic and monitoring tools, with esophageal biopsy remaining the gold standard
• Delayed diagnosis and under-recognition in early disease due to non-specific, overlapping symptoms
• Limited disease-modifying therapies and persistent fibrostenosis in a subset of patients
• Drug discontinuations due to target and endpoint limitations, as seen with several pipeline setbacks
• High cost of approved biologic therapies, with annual treatment costs reaching tens of thousands of dollars
• Variable treatment response and high relapse rates limiting long-term disease control with existing options

Scope of the Eosinophilic Esophagitis Market Report

• Study Period: 2022–2036
• Forecast Period: 2026–2036
• Coverage: 7MM
• Key Eosinophilic Esophagitis Companies: AstraZeneca and Amgen, Ellodi Pharmaceuticals, Revolo Biotherapeutics, Phathom Pharmaceuticals, Uniquity Bio, EsoCap AG, DBV Technologies, Eupraxia Pharmaceuticals, and others
• Key Eosinophilic Esophagitis Therapies: DUPIXENT (dupilumab), EOHILIA (budesonide oral suspension), JORVEZA (budesonide ODT), TEZSPIRE (tezepelumab), APT-1011, IRL201104, VOQUEZNA (vonoprazan), Solrikitug, ESO-101, EP-104GI, and others
• EoE Market Segmented By: Total market size, market size by therapies, market size by class
• Analysis Covered: KOL views, SWOT analysis, conjoint analysis, unmet need, market drivers and barriers, market access and reimbursement

Discover more about therapies set to grab major Eosinophilic Esophagitis market share @ Eosinophilic Esophagitis Treatment Market

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.